masi stock: Masimo Corporation Overview

Masimo Corporation (MASI)

Masimo stock refers to the Nasdaq-listed equity ticker MASI, representing Masimo Corporation, a U.S.-based medical-technology company best known for noninvasive patient monitoring technologies. This article explains what masi stock is, summarizes Masimo's history, products, financial profile, corporate events through 2024–2025, and provides neutral, source-based context useful to readers seeking factual information about the company and its publicly traded shares.

Infobox summary (Stock snapshot)

The following items outline the typical contents of a stock snapshot infobox for masi stock and Masimo Corporation:

• Ticker: MASI (commonly referenced as "masi stock")
• Exchange: Nasdaq (primary listing)
• Industry: Medical Devices / Healthcare Technology
• Headquarters: Irvine, California, United States
• Key financials (most recent fiscal year filings): annual revenue around $2.0–2.1 billion (FY2024), with net income that fluctuated and included a reported net loss in some 2024 filings—see SEC filings for exact figures
• Shares outstanding: reported in company filings; please consult the latest 10-K/10-Q for the current count
• Market cap band: mid-cap, roughly in the $8–10 billion range in late 2024–early 2025 (varies with market price)
• Latest trading price and 52-week range: updated prices and ranges change daily—use official market quote providers; masi stock's intraday and historical price ranges are tracked on platforms such as Nasdaq and major financial data services (see References and data sources)

Note: the infobox above is a descriptive checklist. Exact numeric values (market cap, shares outstanding, trailing revenue and net income) must be updated using the company’s latest SEC filings, investor presentations, or real-time market data before publication.

History

Founding and early development

Masimo Corporation was founded in 1989 by entrepreneur and engineer Joe Kiani. The company initially focused on improving pulse oximetry—noninvasive measurement of blood oxygen saturation—and developed proprietary technologies to improve signal accuracy under motion and low perfusion conditions. Masimo’s Masimo SET (Signal Extraction Technology) became a core product differentiator, enabling more reliable pulse oximetry readings in challenging clinical settings.

Over time, Masimo expanded beyond single-parameter pulse oximeters to broader hospital and clinical monitoring systems. The company’s research and development emphasized noninvasive monitoring, additional physiologic parameters, and integration with hospital information systems. Masimo’s clinical devices found adoption in operating rooms, intensive care units, emergency medicine, neonatal care, and increasingly in remote and home-monitoring contexts.

Recent corporate events

Masimo experienced several high-profile corporate events during the 2024–2025 period. Shareholder activism, board contests, and leadership changes were publicly reported as material developments. In 2024, the company underwent a contentious boardroom period that included activist involvement and challenges to existing governance. These events culminated in leadership transitions and a reconfigured board composition in late 2024 and into 2025.

Management changes included a CEO transition and related updates to the executive team. Public filings and press releases from Masimo’s investor relations site provide primary documentation of board votes, director appointments, and CEO succession as reported by the company. These corporate governance events contributed to stock volatility for masi stock across 2024–2025.

In 2025, Masimo reported strategic portfolio adjustments that included the sale or divestiture of certain consumer and non-healthcare business elements—most notably parts of its premium audio and in-vehicle audio licensing activities. Those moves were positioned as a refocusing on core healthcare monitoring businesses; reported sales and their financial terms should be verified in the company’s transaction disclosures.

Products and technology

Healthcare monitoring products

Masimo’s core competencies are in physiological monitoring and signal processing. Key product families and technologies include:

• Masimo SET: the company’s foundational pulse oximetry technology designed to deliver more accurate SpO2 and pulse rate readings during patient motion and in low-perfusion states.
• rainbow SET: an extension that measures additional parameters noninvasively using multiple wavelengths, such as arterial oxygen saturation variants, hemoglobin-related indices, and other optical parameters.
• SedLine: brain function monitoring and processed EEG systems used in anesthesia and critical care to track depth of sedation.
• Acoustic respiration monitoring (RRa): noninvasive respiratory rate monitoring using acoustic sensors.
• Regional oximetry: cerebral and peripheral regional oxygen saturation monitoring used in surgery and critical care.

These technologies are used across clinical settings—operating rooms, PACU (post-anesthesia care), ICUs, general wards, neonatal units, emergency departments, EMS, and home health. Masimo’s devices are typically marketed to hospitals, clinics, ambulance services, and home-care providers. Clinical adoption is influenced by peer-reviewed studies, reimbursement frameworks, and hospital procurement cycles.

Hospital automation and connectivity

Masimo has developed connectivity and hospital automation solutions to integrate bedside monitoring, telemetry, and remote surveillance. Platforms such as Patient SafetyNet and other remote monitoring systems enable centralized surveillance of patient vital signs, alarm management, and escalation workflows.

These platforms aim to reduce alarm fatigue, improve response times, and enable continuous monitoring outside intensive care settings. Integration with electronic health record (EHR) systems, nurse call systems, and hospital IT infrastructures is an important part of Masimo’s hospital automation strategy.

Target customers for these solutions include large hospital systems, integrated delivery networks, ambulatory care centers, and telehealth providers. Masimo also sells direct to hospitals as well as through distributors and OEM relationships for integration into broader clinical systems.

Consumer and non-healthcare products (historical / divested)

Masimo historically developed and marketed certain consumer audio and non-medical products, including premium headphone technologies and automotive audio licensing. These activities were complementary revenue sources but outside the company’s core clinical mission.

According to company statements and market reports, Masimo moved to divest or restructure some of its consumer and audio-related holdings in 2025 to concentrate capital and management attention on healthcare monitoring. Reported sales or separations of audio-business elements in 2025 were framed as strategic portfolio simplification; for exact transaction details, see Masimo’s SEC disclosures and press releases.

Business segments and operations

Masimo historically reported results by business segment separating healthcare monitoring products from non-healthcare revenues. The company operates globally, with sales through multiple channels:

• Direct sales teams targeting large hospital systems and health networks
• Regional distributors serving smaller hospitals and clinics
• OEM partnerships and technology licensing to other medical equipment manufacturers
• E-commerce and retail channels for consumer-oriented products (where applicable)

Geographically, Masimo maintains sales and service operations across North America, Europe, Asia-Pacific, and other international markets. Product support, training, and clinical education are important components of the company’s commercial model, particularly for clinical monitoring equipment where measured outcomes and clinician confidence influence purchasing decisions.

Financial performance

Masimo’s financial performance in recent reporting cycles showed annual revenue near $2.0–2.1 billion for its most recent full fiscal year (FY2024) and company-reported margins reflecting product mix, warranty and service costs, and R&D spending. In late 2024, some filings and reports noted a net loss on a GAAP basis for that period, influenced by restructuring costs, legal reserves, or one-time items in certain quarters.

Key financial themes to note (consistent with public filings and market reports):

• Revenue growth: Masimo’s top-line performance has been driven by adoption of clinical monitoring technologies and the expansion of connected monitoring platforms. Year-over-year growth rates vary by quarter and are susceptible to hospital capital cycles and procurement timing.
• Profitability and margins: gross profit and gross-margin dynamics are influenced by product mix (hardware vs. recurring consumables and services), manufacturing costs, and pricing pressures in competitive markets.
• Cash flow and balance sheet: Masimo historically maintained operating cash flows to fund R&D and working capital needs; specific liquidity positions, credit facilities, and cash balances are disclosed in quarterly and annual reports.

For exact numeric values (revenue, net income or loss, gross profit, and margins), consult the company’s latest 10-K (annual report) and 10-Q (quarterly filings) available via SEC filings and the company’s investor relations materials. Public financial-data providers such as Morningstar and Yahoo Finance also aggregate these metrics for reference.

Stock information

Trading details

masi stock trades on the Nasdaq exchange under the ticker MASI. Trading activity for masi stock commonly shows average daily volumes in the low millions of shares, with intraday liquidity sufficient for most institutional and retail transactions. Market capitalization for Masimo was in the mid-cap band—roughly $8–10 billion in late 2024 and into early 2025—though market cap changes with daily price movements.

Note: When checking masi stock trading or considering execution options, official market data providers and brokerage platforms update real-time quotes and order depth. For users preferring specific platforms, Bitget supports U.S. equity trading services and provides market data—consult Bitget’s trading interface or investor services for platform-specific features.

Historical performance and volatility

masi stock has displayed volatility around several material events, including earnings releases, legal rulings, major contract announcements, and governance contests. Notable price-moving events during the 2024–2025 period included:

• Quarterly earnings that beat or missed consensus estimates
• Publicized litigation outcomes or jury verdicts that had potential material impacts on intellectual property or damages exposure
• Board contests and executive leadership changes that altered investor perceptions of strategic direction
• Announcements of divestitures or major asset sales (for example, reported sales of audio-related business elements in 2025)

Investors and market-watchers commonly track masi stock’s 52-week high and low as a measure of volatility; these ranges and historical returns are published by Nasdaq, Yahoo Finance, Barchart, and other financial-data vendors.

Analyst coverage and ratings

Masimo has attracted coverage from sell-side analysts and independent equity researchers. Consensus ratings have varied across buy/hold/sell categorizations depending on firm-specific models and expectations for revenue growth, margin expansion, and legal risk resolution.

Analyst price targets and recommendations can diverge substantially; no consistent dividend policy has been maintained by Masimo through 2024–2025. Readers should consult recent analyst reports and disclosures for the latest coverage opinions while noting that analyst estimates are forward-looking and subject to change.

Mergers, acquisitions and divestitures

Masimo has pursued selective acquisitions and technology partnerships to augment its monitoring technology portfolio. During the 2024–2025 period, the company made strategic adjustments including reported divestitures of non-core businesses (notably audio-related assets in 2025) to sharpen the focus on healthcare monitoring.

M&A rationale cited by companies in the sector often includes expanding addressable markets, augmenting technology stacks, and improving recurring revenue streams through consumables and services. For specific transaction terms, closing dates, and financial impacts on masi stock, consult Masimo’s public transaction notices and SEC filings.

A related item in the broader technology and semiconductor space—while not directly involving Masimo—illustrates sector consolidation trends: as of Jan 26, 2026, Reuters reported that IonQ agreed to acquire SkyWater Technology for about $1.8 billion to bring semiconductor manufacturing in-house. Though that transaction targets quantum computing and foundry capacity, it signals wider market emphasis on domestic supply chain control that can influence device manufacturers and medical-technology suppliers that rely on specialized components. (As of Jan 26, 2026, Reuters reported the IonQ-SkyWater deal and its terms.)

Litigation and regulatory matters

Masimo has been involved in multiple litigation and regulatory matters that have had material implications for the company and masi stock. These include patent and intellectual-property disputes, regulatory interactions with agencies such as the U.S. Food and Drug Administration (FDA), and commercial contract disputes.

Key points about litigation and regulatory exposure:

• Patent litigation: Masimo has both asserted patents and defended against claims brought by competitors in the clinical monitoring space. Patent disputes can involve claims of infringement, invalidity challenges, and damages awards, any of which have the potential to impact product availability or financial reserves.
• FDA and regulatory interactions: As a medical-device maker, Masimo’s products and certain software/firmware updates are subject to regulatory clearance or approval and post-market surveillance requirements. Regulatory issues can affect product launches and labeling.
• Class actions and shareholder litigation: Corporate governance disputes and contested proxy fights have occasionally led to shareholder actions and related litigation.

Public filings, court dockets, and company disclosures document the status and resolution of these matters. Changes in legal reserves, settlement terms, or appellate outcomes have been material drivers of masi stock price movement in prior reporting periods.

Corporate governance and management

Masimo’s governance profile and executive leadership have been focal points for investors during recent years. Notable governance events include board contests and shareholder-activist engagements in 2024; these events led to changes in board composition and executive roles into 2025.

• Board leadership: Board chair and lead director roles were updated following contested votes; detailed director biographies and committee memberships are provided in proxy statements and corporate governance disclosures.
• Executive team: CEO succession and adjustments to the senior management team were publicly communicated in company press releases and SEC filings; these transitions were material to strategic direction and market perception.
• Shareholder activism: Public activist campaigns and proposals aimed at strategic change have influenced both governance arrangements and public discourse about Masimo’s future priorities.

For accurate, current leadership names and board memberships, consult the latest SEC filings, the company’s annual proxy statement, and investor relations materials.

Risks and investment considerations

This section summarizes principal risk categories historically associated with Masimo and masi stock. The points are neutral, factual risk considerations rather than investment advice.

• Litigation and IP risk: Ongoing or potential patent litigation and intellectual-property claims can lead to damages, injunctions, or licensing obligations that affect operations and financial results.
• Regulatory risk: Medical devices are subject to regulatory oversight worldwide; delays, non-compliance findings, or issuance of warnings can affect product availability and reputation.
• Product concentration and adoption: A meaningful portion of revenue can be tied to a limited set of core technologies. Slower-than-expected clinical adoption or competitive displacement could affect sales growth.
• Competition: Larger medical-device companies and emerging wearable-technology firms compete in monitoring and diagnostic spaces, which can pressure pricing and margins.
• Reimbursement and procurement cycles: Hospital capital budgets, reimbursement rules, and purchasing group decisions can create timing variability in revenue recognition.
• Governance and execution risk: Boardroom disputes and management turnover can create strategic uncertainty and affect investor confidence.
• Financial statement volatility: One-time charges, restructuring costs, or legal settlements can cause swings in reported net income or cash flow.

Readers should review Masimo’s risk disclosures in its annual 10-K filing for a comprehensive and company-acknowledged list of risks.

Market position and competitors

Masimo competes in clinical monitoring and noninvasive measurement technologies. Competitors and peers range from large diversified medical-device manufacturers to specialized monitoring firms and emerging technology entrants in wearables. Competitor dynamics vary by product line:

• Clinical monitoring: Established medtech companies that provide multi-parameter monitors, pulse oximetry, and anesthesia monitoring are principal competitors in hospital markets.
• Wearables and remote monitoring: Consumer-focused wearable makers and health-technology startups create competitive pressure for certain remote or home-monitoring use cases.
• Connectivity and software platforms: Health IT firms and EHR vendors compete for interoperability and hospital integration deals.

Masimo’s positioning leans on proprietary signal-processing methods, a body of clinical publications supporting its technologies, and an installed base of devices and monitoring platforms in hospitals.

Recent news and developments

This section summarizes prominent headlines and company developments through 2024–2025 and notable related sector news into early 2026.

• Boardroom and leadership changes (2024–2025): Public reports documented contested board votes and executive transitions. These governance events were disclosed in SEC filings and company press statements and were material to market evaluations of masi stock.

• Legal outcomes and litigation updates: Litigation decisions and settlements that were material to Masimo’s operations were reported in filings and news coverage. Specific case statuses and outcomes are tracked in Masimo’s SEC reports.

• Divestiture of non-core assets (2025): Masimo publicly reported or was reported by credible sources to have sold certain consumer audio-related business elements in 2025 to streamline focus on core clinical monitoring. Exact terms and financial impacts are detailed in the company’s transaction disclosures.

• Sector-level supply chain and technology consolidation (relevant external event): As of Jan 26, 2026, Reuters reported that IonQ agreed to acquire SkyWater Technology for about $1.8 billion to bring semiconductor manufacturing in-house. While this transaction directly involves the quantum-computing and foundry sectors, it is an example of supply-chain vertical integration and U.S. manufacturing consolidation that can have indirect implications across medical device supply chains requiring specialized semiconductor components. (As of Jan 26, 2026, Reuters reported the IonQ-SkyWater deal.)

• Earnings and financial updates: Quarterly earnings releases during 2024–2025 showed fluctuations in revenue and profitability; some quarters included one-time items affecting net income. Official 10-Q and 8-K filings provide specific quarter-by-quarter detail.

For the most current headlines that may affect masi stock, consult real-time financial news services and official Masimo press releases.

References and data sources

This article is a synthesis of public-domain information and reputable financial reporting. Primary types of sources to verify any factual item here include:

• Masimo investor relations and company press releases (official statements and SEC filings)
• SEC filings (Form 10-K, Form 10-Q, Form 8-K, and proxy statements)
• Nasdaq company page and market data
• Financial-data services and aggregators such as Yahoo Finance, Morningstar, and Barchart for historical and real-time quotes
• Major business and financial news outlets for reporting on corporate events (e.g., Reuters, CNN Markets)
• Industry and clinical publications that evaluate medical-device performance

As noted above, the Reuters item used in this article was reported on Jan 26, 2026, regarding IonQ’s acquisition of SkyWater Technology; that news is presented as a sector context item and is cited with date for timeliness.

See also

• List of medical device companies
• Pulse oximetry and clinical monitoring basics
• Wearable health technology
• Nasdaq-listed medical device companies

External links

Suggested primary pages to consult for verification (use your browser or platform’s research functions to access these):

• Masimo corporate homepage and investor relations
• SEC EDGAR filings for Masimo (10-K, 10-Q, 8-K)
• Nasdaq MASI company page and real-time quotes
• Financial-data pages (Yahoo Finance, Morningstar, Barchart)

Final notes and reading guidance

This article aimed to provide a neutral, structured overview of masi stock and Masimo Corporation’s business, products, governance, financial profile, and material events through the 2024–early 2026 timeframe. For real-time pricing, regulatory filings, and the most recent corporate disclosures, consult official SEC filings and Masimo’s investor relations channels.

If you would like platform-specific guidance for viewing market data or placing trades, Bitget provides tools and market access for U.S. equities; explore Bitget’s trading interface or support center for platform details.

Further reading or data verification can be performed by reviewing the company’s most recent annual report and quarterly filings.